<DOC>
	<DOCNO>NCT01080170</DOCNO>
	<brief_summary>This study explore aromatase inhibitor therapy affect risk factor heart disease postmenopausal woman breast cancer .</brief_summary>
	<brief_title>The Effect Aromatase Inhibitors Cardiovascular Risk Factors Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Ambulatory woman ( aged 6075 ) , new diagnosis nonmetastatic , hormonereceptor positive breast cancer , undergone lumpectomy . They need chemotherapy prescribe yet start anastrazole . All need course radiation therapy part usual care . Participants instructed change physical activity eat habit period study . Comparisons : Identical case except hormonereceptor negative n't need hormonal therapy . Healthy control . Nicotine usage Metastatic breast cancer Need chemotherapy AI anastrazole Usage steroid ( equivalent equal 7.5 mg prednisone x 3 month ) Clinically significant abnormality thyroid function Treatment gonadal hormone replacement therapy within last 3 year Status post unilateral/bilateral surgical oophorectomy Having experience medical event , may confound study outcome [ e.g . heart attack , stroke , cancer ( metastatic newly diagnose within last 5 year , except nonmelanoma skin cancer breast ) , lupus , rheumatoid arthritis , chronic inflammatory disease ] Medicationdependent diabetes mellitus hypercholesterolemia . Gastric surgery Weight loss medication ( prescription counter )</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Aromatase Inhibitor</keyword>
	<keyword>Anastrazole</keyword>
	<keyword>Arimidex</keyword>
	<keyword>Heart disease</keyword>
	<keyword>Lipids</keyword>
	<keyword>Body composition</keyword>
	<keyword>Breast cancer .</keyword>
</DOC>